Your browser doesn't support javascript.
loading
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Vu, Tuan; Meisel, Andreas; Mantegazza, Renato; Annane, Djillali; Katsuno, Masahisa; Aguzzi, Rasha; Enayetallah, Ahmed; Beasley, Kathleen N; Rampal, Nishi; Howard, James F.
Afiliação
  • Vu T; University of South Florida Morsani College of Medicine, Tampa, FL, USA. tvu6@usf.edu.
  • Meisel A; Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Mantegazza R; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Annane D; Hôpital Raymond Poincaré, University of Versailles, Garches, France.
  • Katsuno M; Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Aguzzi R; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
  • Enayetallah A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
  • Beasley KN; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
  • Rampal N; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
  • Howard JF; The University of North Carolina, Chapel Hill, NC, USA.
Neurol Ther ; 12(5): 1435-1438, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37351816
ABSTRACT
This article provides a summary of a previously published paper Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article